Zimmer Biomet Holdings, Inc. $ZBH Shares Purchased by South Dakota Investment Council

South Dakota Investment Council grew its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 36.8% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 112,689 shares of the medical equipment provider’s stock after purchasing an additional 30,303 shares during the period. South Dakota Investment Council’s holdings in Zimmer Biomet were worth $10,278,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in ZBH. Vanguard Group Inc. grew its holdings in Zimmer Biomet by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 23,052,925 shares of the medical equipment provider’s stock worth $2,609,130,000 after buying an additional 166,763 shares in the last quarter. Dodge & Cox boosted its position in Zimmer Biomet by 2.3% during the 1st quarter. Dodge & Cox now owns 19,564,454 shares of the medical equipment provider’s stock worth $2,214,305,000 after acquiring an additional 446,018 shares during the period. Ameriprise Financial Inc. grew its stake in shares of Zimmer Biomet by 236.0% in the first quarter. Ameriprise Financial Inc. now owns 4,568,287 shares of the medical equipment provider’s stock worth $517,039,000 after purchasing an additional 3,208,596 shares in the last quarter. JPMorgan Chase & Co. grew its stake in shares of Zimmer Biomet by 251.3% in the first quarter. JPMorgan Chase & Co. now owns 2,081,381 shares of the medical equipment provider’s stock worth $235,571,000 after purchasing an additional 1,488,918 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Zimmer Biomet by 2.9% during the first quarter. Dimensional Fund Advisors LP now owns 2,058,898 shares of the medical equipment provider’s stock valued at $233,009,000 after purchasing an additional 58,060 shares during the period. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Stock Up 1.2%

ZBH stock opened at $100.77 on Monday. The firm has a market cap of $19.96 billion, a PE ratio of 24.52, a P/E/G ratio of 2.29 and a beta of 0.67. Zimmer Biomet Holdings, Inc. has a 12 month low of $89.22 and a 12 month high of $114.72. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.87 and a quick ratio of 0.96. The firm has a 50 day simple moving average of $101.45 and a 200 day simple moving average of $97.62.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.98 by $0.09. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The firm had revenue of $2.08 billion for the quarter, compared to analyst estimates of $2.06 billion. During the same quarter in the previous year, the business posted $2.01 earnings per share. The firm’s quarterly revenue was up 7.0% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Equities research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th were given a dividend of $0.24 per share. The ex-dividend date of this dividend was Tuesday, September 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. Zimmer Biomet’s payout ratio is 23.36%.

Insider Activity at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,500 shares of the stock in a transaction on Monday, September 8th. The stock was sold at an average price of $104.15, for a total value of $156,225.00. Following the completion of the transaction, the senior vice president owned 6,833 shares in the company, valued at $711,656.95. This trade represents a 18.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 1.39% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the stock. Stifel Nicolaus increased their target price on shares of Zimmer Biomet from $115.00 to $118.00 and gave the company a “buy” rating in a research report on Friday, September 19th. Royal Bank Of Canada set a $111.00 price target on shares of Zimmer Biomet in a research note on Friday, October 10th. BTIG Research raised their price objective on shares of Zimmer Biomet from $118.00 to $122.00 and gave the company a “buy” rating in a research note on Monday, October 13th. Rothschild & Co Redburn began coverage on Zimmer Biomet in a research report on Thursday, September 18th. They issued a “buy” rating and a $130.00 target price for the company. Finally, Raymond James Financial increased their price target on Zimmer Biomet from $104.00 to $113.00 and gave the company an “outperform” rating in a research note on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $111.94.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.